There are 449 resources available
LBA2 - Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study
Presenter: Mark Awad
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Mechanism of IO resistance
Presenter: Myung-Ju Ahn
Session: Overcoming IO resistance
Resources:
Slides
Webcast
194MO - Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results
Presenter: Yan Zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Performance status versus age
Presenter: Sabine Schmid
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
Novel co-stimuatory and co-inhibitory drugs (LAG3,TIM3, TIGIT, bispecific, OX-40, 41BB, BiTE etc)
Presenter: Alfredo Addeo
Session: Overcoming IO resistance
Resources:
Slides
Webcast
Polypharmacy and concomitant medications as prognostic factors for immune checkpoint blockade
Presenter: Alessio Cortellini
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
Cytokines and other immune modulators
Presenter: Paola Nisticò
Session: Overcoming IO resistance
Resources:
Slides
Webcast
Invited Discussant LBA2 and 194MO
Presenter: Gerard Hanna
Session: Mini Oral session 1
Resources:
Slides
Webcast
Personalised cancer vaccine and cell therapy
Presenter: Mark Awad
Session: Overcoming IO resistance
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast